Experienced in Philadelphia-Negative Chronic Myeloid Leukemia

Dr. Steven W. Corso

Hematology Oncology | Hematology | Oncology
Spartanburg Medical Center
380 Serpentine Dr, Suite 200, 
Spartanburg, SC 
Accepting New Patients
Experienced in Philadelphia-Negative Chronic Myeloid Leukemia
Spartanburg Medical Center
380 Serpentine Dr, Suite 200, 
Spartanburg, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Steven Corso is a Hematologist Oncology specialist and a Hematologist in Spartanburg, South Carolina. Dr. Corso is rated as an Experienced provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Leukocytosis. Dr. Corso is currently accepting new patients.

His clinical research consists of co-authoring 7 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in SC
Hospital Affiliations
Spartanburg Medical Center
Pelham Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

SPARTANBURG MEDICAL CENTER
380 Serpentine Dr, Suite 200, Spartanburg, SC 29303

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
FDG PET to Assess Therapeutic Response in Patients With Bone-Dominant Metastatic Breast Cancer, FEATURE
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Other, Procedure
Study Phase: Phase 2
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2024
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)
Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Procedure, Drug, Radiation
Study Phase: Not Applicable
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2024
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
Pilot Clinical Trial Evaluating the Utility of Topical Cryotherapy to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Controlled Trial
Pilot Clinical Trial Evaluating the Utility of Topical Cryotherapy to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Controlled Trial
Enrollment Status: Completed
Publish Date: September 30, 2019
Intervention Type: Other, Drug, Procedure
Study Phase: Not Applicable
View 10 Less Clinical Trials

7 Total Publications

Systemic inflammation and changes in physical well-being in patients with breast cancer: a longitudinal study in community oncology settings.
Systemic inflammation and changes in physical well-being in patients with breast cancer: a longitudinal study in community oncology settings.
Journal: The oncologist
Published: December 07, 2023
Similar Doctors
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Xuezhong Yang
Hematology Oncology | Hematology | Oncology
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Xuezhong Yang
Hematology Oncology | Hematology | Oncology

Bon Secours Medical Group Greenville Specialty Care LLC

104 Innovation Dr, Suite 2000, 
Greenville, SC 
 (24.3 miles away)
864-603-6300
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Xuezhong Yang is a Hematologist Oncology specialist and a Hematologist in Greenville, South Carolina. Dr. Yang is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Childhood Iron Deficiency Anemia, Lung Cancer, Pleuropulmonary Blastoma, Thrombocytopenia, and Bone Marrow Aspiration. Dr. Yang is currently accepting new patients.

John K. Hill
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. John K. Hill
Hematology Oncology | Hematology | Oncology
Distinguished in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. John K. Hill
Hematology Oncology | Hematology | Oncology

Henderson County Hospital Corporation

805 6th Ave W, 
Hendersonville, NC 
 (38.8 miles away)
828-696-1330
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Hill is a Hematologist Oncology specialist and a Hematologist in Hendersonville, North Carolina. Dr. Hill is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Large-Cell Immunoblastic Lymphoma. Dr. Hill is currently accepting new patients.

Sini J. Kalapurakal
Advanced in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Sini J. Kalapurakal
Hematology | Oncology | Internal Medicine
Advanced in Philadelphia-Negative Chronic Myeloid Leukemia
Dr. Sini J. Kalapurakal
Hematology | Oncology | Internal Medicine

Atrium Health Levine Cancer Institute, A Facility Of Atrium Health Cleveland

136 Sparks Drive, 
Forest City, NC 
 (23.7 miles away)
828-288-6320
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sini Kalapurakal is a Hematologist and an Oncologist in Forest City, North Carolina. Dr. Kalapurakal is rated as a Distinguished provider by MediFind in the treatment of Philadelphia-Negative Chronic Myeloid Leukemia. Her top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Thrombocytopenia, Philadelphia-Negative Chronic Myeloid Leukemia, and Chronic Myelogenous Leukemia (CML). Dr. Kalapurakal is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Corso's expertise for a condition
ConditionClose
    View All 22 Advanced Conditions
    View All 100 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile